USPTO 2015–2025 USPTO PatentsView US Corporation

Arcturus Therapeutics, Inc.

USPTO PatentsView assignee record - 59 granted patents across 15 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

18.7

Avg claims per patent

+27%

5-year filing velocity

The verdict

Arcturus holds 59 US patents across 15 technology areas, rank #5,734 of 50,000 tracked assignees.

#5,734
of 50,000 US assignees by volume: Top 26%
by Innovation Score (44.1/100): 18.7
avg claims per patent: +27%
filing velocity, last 5 yrs

Portfolio overview

Arcturus Therapeutics, Inc. has been granted 59 US utility patents between 2015 and 2025, placing Arcturus Therapeutics, Inc. at rank #5,734 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.7 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Arcturus Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Arcturus sits between Zonar Systems, Inc. (60 patents, rank #5,730) and Aerin Medical Inc. (59 patents, rank #5,738) - the closest US assignees by grant volume. The composite Innovation Score of 44.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 33 grants, compared with 26 in the 2015–2019 window, a +27% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Arcturus Therapeutics, Inc.'s 18.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Arcturus Therapeutics, Inc. against peers pursuing similar technology classes.

Zonar Systems

60
[24]7 ai

60
mophie

60
Alaxala Networks

59
Arris Technology

59
Auras Technology

59
Accuvein

59
Aerin Medical

59
Arcturus Therapeu… ◀

59

What this shows Arcturus holds 59 patents at rank #5,734, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Arcturus

By rank, the assignees closest to #5,734 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Arcturus's primary technology class.

Arcturus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Arcturus Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	1.7%
2016	4	6.8%
2017	6	10.2%
2018	6	10.2%
2019	9	15.3%
2020	7	11.9%
2021	4	6.8%
2022	3	5.1%
2023	5	8.5%
2024	7	11.9%
2025	7	11.9%

Which technologies does Arcturus Therapeutics, Inc. patent most?

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 47

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 46

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 33

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 18

C07J - STEROIDS 12

C11C - FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM 10

C07K - PEPTIDES 9

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 8

C12Y - ENZYMES 5

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 4

A23D - EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS 2

B82Y - SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 1

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 1

C07D - HETEROCYCLIC COMPOUNDS 1

Top 15 of 15 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#5,734

Across all tracked assignees

Innovation Score

44.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Arcturus Therapeutics, Inc. hold?

Arcturus Therapeutics, Inc. holds 59 US granted patents filed between 2015 and 2025, spanning 15 technology areas.

What is Arcturus Therapeutics, Inc.'s Innovation Score?

Arcturus Therapeutics, Inc. has an Innovation Score of 44.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Arcturus Therapeutics, Inc. focus on?

Arcturus Therapeutics, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 47 patents. The company has filed patents in 15 CPC subclasses total.

Is Arcturus Therapeutics, Inc.'s patent filing rate increasing or decreasing?

Arcturus Therapeutics, Inc.'s recent filing velocity is +27% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Arcturus Therapeutics, Inc.'s patents?

Arcturus Therapeutics, Inc.'s patents average 18.7 claims each. This falls within the standard range, providing solid legal coverage.

How is the Arcturus Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Arcturus's 59 grants land it in the top 26% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Arcturus ranks #5,734 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.